Literature DB >> 2471709

Human thyrotropin receptor subunits characterized by thyrotropin affinity purification and western blotting.

P J Leedman1, J D Newman, L C Harrison.   

Abstract

We studied the subunit structure of the human TSH receptor in thyroid tissue from patients with Graves' disease and multinodular goiter by TSH affinity chromatography, immunoprecipitation with Graves' immunoglobulins (Igs), and a modified technique of Western blotting. Human TSH receptor-binding activity was purified about 1,270-fold by sequential affinity chromatography on wheat germ lectin-agarose and TSH-agarose. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of nonreduced affinity-purified receptors eluted in sodium dodecyl sulfate sample buffer revealed three noncovalently linked subunits of 70,000, 50,000, and 35,000 mol wt. When reduced, a major subunit of 25,000 mol wt was identified. When 3 mol/L NaCl was used to elute affinity-purified receptors only the 50,000 mol wt nonreduced subunit was detected. This subunit bound [125I]bovine TSH and was precipitated by Graves' Igs. Modifications to the conventional Western blotting technique enabled thyroglobulin components (approximately 220,000 mol wt), thyroid microsomal antigen (a doublet of approximately 110,000 mol wt), and putative TSH receptor subunits of 70,000 and 50,000 mol wt to be identified in thyroid particulate membranes by Graves' Igs. Blotting of affinity-purified receptors eluted in sodium dodecyl sulfate sample buffer revealed subunits of either 70,000 or 50,000 mol wt, with a minority of Graves' serum samples. We conclude that the nonreduced human TSH receptor is an oligomeric complex comprising three different subunits of 70,000, 50,000, and 35,000 mol wt. The reduced receptor exists as a single subunit of 25,000 mol wt, which may be disulfide linked to form the higher mol wt forms. The 70,000 and 50,000 mol wt subunits contain epitopes that bind Graves' Igs in modified Western blots, thus directly confirming that the human TSH receptor is a target for Graves' Igs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471709     DOI: 10.1210/jcem-69-1-134

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Affinity-based separations and purifications. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1991-01       Impact factor: 2.926

2.  Two-subunit structure of the human thyrotropin receptor.

Authors:  H Loosfelt; C Pichon; A Jolivet; M Misrahi; B Caillou; M Jamous; B Vannier; E Milgrom
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

3.  Direct evidence that ganglioside is an integral component of the thyrotropin receptor.

Authors:  W Kielczynski; L C Harrison; P J Leedman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

4.  Cloning from the thyroid of a protein related to actin binding protein that is recognized by Graves disease immunoglobulins.

Authors:  P J Leedman; B Faulkner-Jones; D S Cram; P J Harrison; J West; E O'Brien; R Simpson; R L Coppel; L C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

5.  Immunogenicity of a unique region of the human thyrotropin receptor.

Authors:  E V Nagy; H B Burch; Y G Lukes; F E Carr; S Kosugi; L D Kohn; K D Burman
Journal:  J Endocrinol Invest       Date:  1993 Jul-Aug       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.